Literature DB >> 27241922

Radical hysterectomy after chemoradiation in FIGO stage III cervical cancer patients versus chemoradiation and brachytherapy: Complications and 3-years survival.

F Fanfani1, E Vizza2, F Landoni3, P de Iaco4, G Ferrandina5, G Corrado2, V Gallotta6, M A Gambacorta7, A Fagotti6, G Monterossi6, A M Perrone4, R Lazzari8, S P Colangione8, G Scambia6.   

Abstract

BACKGROUND: To compare patterns and rates of early and late complications, and survival outcome in FIGO stage III cervical cancer patients underwent to radical hysterectomy after chemo-radiation (CT-RT) vs. chemo-radiation alone.
METHODS: Between May 1996 and April 2013 150 FIGO stage III cervical cancer patients were treated. We divide patients according to type of treatment: 77 were submitted to standard treatment (Group A), and 73 to completion hysterectomy after chemo-radiation (Group B).
RESULTS: The baseline characteristics of the 2 groups were superimposable. We observed lower intra-operative and treatment-related early urinary and gastro-intestinal complications in Group B with respect to Group A (p < 0.001). Vascular complications were registered only in Group B (p < 0.001). We found a significantly higher rate of local recurrences in the Group A than in the Group B (p < 0.002). We registered 29 deaths in the Group A and 22 in the Group B (p = 0.021). The 3-years disease-free survival rate in the Group A and in the Group B was 62.9% and 68.3%, respectively (p = 0.686), and the 3-years overall survival rate in the Group A and in the Group B was 63.2% and 67.7%, respectively (p = 0.675).
CONCLUSIONS: This study confirms that radical hysterectomy after CT-RT is an effective therapeutic approach for advanced cervical cancer. Further prospective and randomized studies should be performed in order to solve the question about the standard approach, and how the different pattern of complication could impact on the quality of life.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Chemoradiation; Radical hysterectomy

Mesh:

Year:  2016        PMID: 27241922     DOI: 10.1016/j.ejso.2016.05.011

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

1.  The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study.

Authors:  Vittoria Rufini; Angela Collarino; Maria Lucia Calcagni; Guido Maria Meduri; Valentina Fuoco; Tina Pasciuto; Antonia Carla Testa; Gabriella Ferrandina; Maria Antonietta Gambacorta; Maura Campitelli; Benedetta Gui; Gianfranco Zannoni; Riccardo Manfredi; Giovanni Scambia; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

2.  Long-Term Results of Concurrent Chemoradiotherapy Combined with Anti-EGFR Monoclonal Antibody Prior to Surgery in Locally Advanced Cervical Cancer: A Single-Institute Prospective Study.

Authors:  Defeng Qing; Yuying Wu; Xu Liu; Hailan Jiang; Chaohua Zhu; Pei Liu; Junming Dang; Xianglong Li; Zhaohong Chen; Xianfeng Long; Qiang Pang; Luxing Peng; Shan Deng; Junzhao Gu; Renfeng Zhao; Changyi Chen; Heming Lu
Journal:  Cancer Manag Res       Date:  2020-12-01       Impact factor: 3.989

3.  Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

Authors:  Yunhai Chuai; Ivana Rizzuto; Xia Zhang; Ying Li; Guanghai Dai; Sophie J Otter; Rasiah Bharathan; Alexandra Stewart; Aiming Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

4.  Individualized pelvic lymphadenectomy should follow neoadjuvant concurrent chemoradiotherapy for locally advanced cervical cancer.

Authors:  Li-Chun Wei; Xin Li; Ying Zhang; Yun-Zhi Dang; Wei-Wei Li; Jian-Ping Li; Li-Na Zhao; Shu-Juan Liu; Xia Li; Mei Shi
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

5.  HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3.

Authors:  Sang Ah Yi; Go Woon Kim; Jung Yoo; Jeung-Whan Han; So Hee Kwon
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

6.  Chemoradiotherapy alone vs. chemoradiotherapy and hysterectomy for locally advanced cervical cancer: A systematic review and updated meta-analysis.

Authors:  Weijia Lu; Canxiong Lu; Zhiwu Yu; Lei Gao
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

7.  Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy.

Authors:  Munetaka Takekuma; Fumiaki Takahashi; Seiji Mabuchi; Wataru Kudaka; Koji Horie; Mariko Ikeda; Ayumi Shikama; Akira Mitsuhashi; Shoji Nagao; Shiro Suzuki; Mika Mizuno; Shin Nishio; Hideki Tokunaga; Yukinobu Ota; Takahiro Kasamatsu; Ryo Kitagawa; Takafumi Toita; Hiroaki Kobayashi; Mitsuya Ishikawa; Nobuo Yaegashi
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

8.  The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/chemoradiotherapy: a meta-analysis.

Authors:  Dan Shi; Zhenzhen Liang; Cheng Zhang; Huaiyu Zhang; Xiaodong Liu
Journal:  BMC Cancer       Date:  2018-03-20       Impact factor: 4.430

9.  A prognostic model guides surgical resection in cervical squamous cell carcinoma.

Authors:  Baiqiang Liang; Haibing Yu; Lianfang Huang; Haiqing Luo; Xiao Zhu
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

Review 10.  Radiomics-based prediction of two-year clinical outcome in locally advanced cervical cancer patients undergoing neoadjuvant chemoradiotherapy.

Authors:  Rosa Autorino; Benedetta Gui; Giulia Panza; Luca Boldrini; Davide Cusumano; Luca Russo; Alessia Nardangeli; Salvatore Persiani; Maura Campitelli; Gabriella Ferrandina; Gabriella Macchia; Vincenzo Valentini; Maria Antonietta Gambacorta; Riccardo Manfredi
Journal:  Radiol Med       Date:  2022-03-24       Impact factor: 6.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.